A 62-year-old female with a 40-pack-year smoking history presents with a 2-month history of progressive weakness, polyuria, and polydipsia. She reports recent-onset diplopia and ptosis of the right eyelid. Serum sodium is 118 mEq/L (normal 135–145), and serum osmolality is 245 mOsm/kg (normal 280–295). Urine osmolality is 580 mOsm/kg. Chest X-ray reveals a 3 cm left perihilar mass with ipsilateral hilar lymphadenopathy but no contralateral involvement or distant metastases. Bronchoscopy with biopsy confirms small cell carcinoma. Which of the following paraneoplastic syndromes is this patient most likely experiencing, and what is the underlying mechanism?

Explanation

## Clinical Presentation Analysis ### Key Clinical Findings **High-Yield:** The patient presents with: - **Hyponatremia** (Na 118 mEq/L) with low serum osmolality (245 mOsm/kg) - **Inappropriately concentrated urine** (osmolality 580 mOsm/kg despite hypo-osmolar serum) - **Neuropsychiatric symptoms:** weakness, altered mental status (implied by diplopia/ptosis confusion) - **Limited-stage SCLC** (left perihilar, ipsilateral hilar nodes only — no contralateral or distant metastases) **Key Point:** This constellation of findings is pathognomonic for **Syndrome of Inappropriate Antidiuretic Hormone (SIADH)** secretion. ## Diagnostic Criteria for SIADH | Criterion | Patient's Finding | Normal Range | |-----------|-------------------|---------------| | Serum sodium | 118 mEq/L | 135–145 mEq/L | | Serum osmolality | 245 mOsm/kg | 280–295 mOsm/kg | | Urine osmolality | 580 mOsm/kg | <100 mOsm/kg (if serum hypo-osmolar) | | Urine sodium | (Presumed elevated) | >40 mEq/L in SIADH | | TSH, cortisol | (Presumed normal) | Normal | | Volume status | Euvolemic | Clinically euvolemic | **Clinical Pearl:** SIADH is the most common paraneoplastic endocrine syndrome in SCLC, occurring in 10–15% of cases. It results from **ectopic ADH (vasopressin) production** by neuroendocrine tumor cells. ## Mechanism of Ectopic ADH Production ```mermaid flowchart TD A[SCLC cells]:::outcome --> B[Neuroendocrine differentiation]:::outcome B --> C[Ectopic ADH synthesis and release]:::action C --> D[Increased water reabsorption in collecting duct]:::action D --> E[Hyponatremia + hypo-osmolality]:::outcome E --> F[Inappropriately concentrated urine]:::outcome F --> G[Neuropsychiatric symptoms<br/>Seizures, confusion, coma]:::urgent ``` **Key Point:** SCLC is a **neuroendocrine malignancy** with high propensity for ectopic hormone production. The tumor cells synthesize and secrete ADH (vasopressin) autonomously, leading to: 1. Increased aquaporin-2 expression in renal collecting duct 2. Enhanced water reabsorption 3. Dilutional hyponatremia and hypo-osmolality 4. Paradoxically concentrated urine (osmolality >serum osmolality) ## Paraneoplastic Syndromes in SCLC | Syndrome | Mechanism | Frequency | Clinical Features | |----------|-----------|-----------|-------------------| | **SIADH** | Ectopic ADH | 10–15% | Hyponatremia, hypo-osmolality, concentrated urine | | **Cushing syndrome** | Ectopic ACTH | 2–5% | Hypokalemia, metabolic alkalosis, hypertension, hyperglycemia | | **Eaton-Lambert** | Anti-VGCC antibodies | 3–5% | Proximal muscle weakness, autonomic dysfunction, areflexia | | **Myasthenia gravis** | Anti-AChR antibodies | <1% | Ocular/bulbar/generalized weakness, fatigability | **Mnemonic:** **ACES** — paraneoplastic syndromes in SCLC: - **A**DIADH (most common) - **C**ushing syndrome - **E**aton-Lambert myasthenic syndrome - **S**ubacute sensory neuropathy ## Why Other Options Are Incorrect **Option 1 (Eaton-Lambert):** While Eaton-Lambert is a paraneoplastic syndrome in SCLC (3–5% incidence), it presents with **proximal muscle weakness, diminished reflexes, and autonomic dysfunction** — NOT hyponatremia. The mechanism involves **anti-VGCC (voltage-gated calcium channel) antibodies** affecting presynaptic neuromuscular transmission. The patient's hyponatremia and SIADH are not explained by this diagnosis. **Option 2 (Cushing syndrome):** Ectopic ACTH production by SCLC causes Cushing syndrome in 2–5% of cases, presenting with **hypokalemia, metabolic alkalosis, hypertension, and hyperglycemia** — NOT hyponatremia. The patient's electrolyte abnormality (hyponatremia with low osmolality) is inconsistent with ACTH-secreting tumors. **Option 3 (Myasthenia gravis):** MG is caused by **anti-acetylcholine receptor (anti-AChR) antibodies** and presents with **ocular weakness (ptosis, diplopia), bulbar symptoms, and fatigability** — features that can overlap with the patient's presentation. However, MG does NOT cause hyponatremia or SIADH. The diplopia and ptosis in this patient are secondary to **hyponatremia-induced neuropsychiatric symptoms** (confusion, weakness), not primary neuromuscular junction dysfunction. **Warning:** Do NOT confuse the neuropsychiatric symptoms of severe hyponatremia (confusion, weakness, seizures) with primary neurological paraneoplastic syndromes. The hyponatremia and SIADH are the primary diagnosis here. ## Clinical Management Implications **High-Yield:** Treatment of SIADH in SCLC includes: 1. **Fluid restriction** (500–1000 mL/day) — first-line for asymptomatic hyponatremia 2. **Hypertonic saline** (3%) — for symptomatic or severe hyponatremia (<120 mEq/L with seizures) 3. **Chemotherapy** — addresses the underlying malignancy and often resolves SIADH 4. **Vaptans** (vasopressin antagonists) — if refractory to fluid restriction [cite:Robbins 10e Ch 15; Harrison 21e Ch 105]